Symbols

PPCB

Propanc Biopharma·NASDAQ

--(--)

7.49 / 10

Outperform

Analyst coverage is absent, but fund‑flow is favorable (7.49/10). Overall inflow ratio ~0.45, small‑cap investors are net buyers, while block, medium, large and extra‑large flows are negative. Liquidity remains decent, yet the prevailing negative trend advises caution.

Fund Flow Rating

Is money flowing into or out of PPCB?

PPCB holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.49/10 (Outperform).